...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Free
Message: BETonMACE Placebo Estimate

Bear based on what you said, I guess Resverlogix will need to make the necessary corrections.

"This PAV regression exceeded the trial's pre-specified PAV endpoint (-0.6%) by more than two-fold."

https://www.resverlogix.com/investors/news?article=492

 

Koo

 

Share
New Message
Please login to post a reply